NASDAQ: $SRRK A New Milestone in SMA Treatment The landscape for treating Spinal Muscular Atrophy (SMA) has officially evolved. The FDA has granted approval for Isembyld (apitegromab), a pioneering muscle-targeted therapy designed to improve motor function in both children and adults living with this challenging condition. What is Isembyld? Isembyld is a myostatin inhibitor. Unlike…